NO963851L - biotin derivative - Google Patents
biotin derivativeInfo
- Publication number
- NO963851L NO963851L NO963851A NO963851A NO963851L NO 963851 L NO963851 L NO 963851L NO 963851 A NO963851 A NO 963851A NO 963851 A NO963851 A NO 963851A NO 963851 L NO963851 L NO 963851L
- Authority
- NO
- Norway
- Prior art keywords
- asp
- ala
- pro
- lys
- gly
- Prior art date
Links
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 title 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 4
- 125000000539 amino acid group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 abstract 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 2
- 102000007079 Peptide Fragments Human genes 0.000 abstract 2
- 229960002685 biotin Drugs 0.000 abstract 2
- 235000020958 biotin Nutrition 0.000 abstract 2
- 239000011616 biotin Substances 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 abstract 1
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 abstract 1
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 abstract 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 abstract 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 abstract 1
- OCSACVPBMIYNJE-GUBZILKMSA-N Pro-Arg-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O OCSACVPBMIYNJE-GUBZILKMSA-N 0.000 abstract 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 abstract 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 abstract 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 abstract 1
- 108010041407 alanylaspartic acid Proteins 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108010004914 prolylarginine Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
Abstract
Biotin derivs. of formula (I), opt. (where appropriate) in D- or L-form, and their salts are new, where Q is absent, or is NH-(CH2)n-CO or NH-(CH2)n-NH; R<1> = X-Arg-Gly-Asp-Y, A-Cys(R<2>)-B-U or cyclo-(Arg-Gly-Asp-Z), Z being attached in the side chain of Q or (where Q is absent) to biotin; X, Y = an amino acid residue or a di-, tri-, tetra- or pentapeptide residue, the amino acids being selected from Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, 4-halo-Phe, His, homo-Phe, Ile, Leu, Lys, Met, Nle, Phe, Phg, Pro, Ser, Thr, Trp, Tyr and Val and their derivs.; A is absent, or is Asp or a peptide fragment selected from Ala-Asp, Thr-Ala-Asp, Lys-Thr-Ala-Asp, Lys-Thr-Ala-Asn, Lys-Thr-Gly-Asp, Lys-Ala-Ala-Asp, Arg-Thr-Ala-Asp, Ser-Ala-Asp, Gln-Ser-Ala-Asp, Glp-Ser-Ala-Asp, Gly-Lys-Thr-Ala-Asp, Asn-Gly-Lys-Thr-Ala-Asp, Ile-Ser-Ala-Gly, Arg-Ser-Ala-Gly, Cys-Asn-Gly-Lys-Thr-Ala-Asp, Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp, Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp, Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp, Gly-Lys-Thr-Cys(Trt)-Asp, Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp or Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp; B is (i) absent, (ii) OH, Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, 4-halo-Phe, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val or an N-methylated deriv. of these, or (iii) a peptide fragment selected from Pro-Arg, Pro-Arg-Asn, Pro-Arg-Asn-Pro, Pro-Arg-Asn-Pro-His, Pro-Arg-Asn-Pro-His-Lys, Pro-Arg-Asn-Pro-His-Lys-Gly, Pro-Arg-Asn-Pro-His-Lys-Gly-Pro, Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala or Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr; R<2> = H, 1-6C alkyl, Trt, Dpm or Bzl; U = OH, OR<9>, NH2, NHR<9> or N(R<9>)2; Z = an amino acid residue or a di, tri- or tetrapeptide residue, the amino acids being selected from Ala, Asn, Asp, Arg, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val and M and derivs. of these, where the amino acid residues are linked together in peptide fashion via the alpha -amino and alpha -carboxy gps.; provided that an amino acid residue M is always present; M = the residue of an amino acid of formula NH(R<8>)-CH(R<3>)-COOH; R<3> = a gp. -R<5>-R<4>, -R<6>-R<4> or -R<7>-R<4>; R<4> = OH, NH2, SH or COOH; R<5> = 1-6C alkylene; R<6> = 7-14C alkylenephenyl; R<7> = 8-14C alkylenephenylalkylene; R<8> = H, 1-6C alkyl or 7-12C alkylenephenyl; R<9> = 1-6C alkyl; halo = F, Cl, Br or I; n = 1-10; Glp = pyroglutamic acid; Phg = phenylglycine; Trt = trityl; provided that when R<1> is a gp. A-Cys(R<2>)-B-U, then only one of A and B may be absent.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19534016A DE19534016A1 (en) | 1995-09-14 | 1995-09-14 | Biotin derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963851D0 NO963851D0 (en) | 1996-09-13 |
| NO963851L true NO963851L (en) | 1997-03-17 |
| NO314694B1 NO314694B1 (en) | 2003-05-05 |
Family
ID=7772112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963851A NO314694B1 (en) | 1995-09-14 | 1996-09-13 | Biotin derivatives, pharmaceutical preparations containing them, and uses of the compounds |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0771818B1 (en) |
| JP (1) | JP4127325B2 (en) |
| KR (1) | KR970015597A (en) |
| CN (1) | CN1168738C (en) |
| AT (1) | ATE215558T1 (en) |
| AU (1) | AU719307B2 (en) |
| BR (1) | BR9603741A (en) |
| CA (1) | CA2185394C (en) |
| CZ (1) | CZ291506B6 (en) |
| DE (2) | DE19534016A1 (en) |
| DK (1) | DK0771818T3 (en) |
| ES (1) | ES2174007T3 (en) |
| HU (1) | HUP9602223A3 (en) |
| MX (1) | MX9604019A (en) |
| NO (1) | NO314694B1 (en) |
| PL (1) | PL316069A1 (en) |
| PT (1) | PT771818E (en) |
| RU (1) | RU2171807C2 (en) |
| SI (1) | SI0771818T1 (en) |
| SK (1) | SK283129B6 (en) |
| TW (1) | TW517063B (en) |
| UA (1) | UA41981C2 (en) |
| ZA (1) | ZA967765B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9916536A (en) | 1998-12-23 | 2002-01-02 | Searle & Co | Method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and, combination |
| WO2001058931A1 (en) * | 2000-02-11 | 2001-08-16 | Duke University | Method of treating disorders of the eye |
| KR100778633B1 (en) * | 2007-04-13 | 2007-11-28 | 성균관대학교산학협력단 | Glp-1 derivative linked biotin and biotin-polyethylene glycol, method for the preparation thereof and pharmaceutical composition comprising the same |
| CN101990425B (en) * | 2008-04-08 | 2016-01-20 | 默克专利股份有限公司 | Comprise compositions and the using method of cyclic peptide |
| CN108956790A (en) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | Application of one group of amino acid tags object in acute kidney injury diagnostic kit |
| CN113827591B (en) * | 2021-11-09 | 2023-06-09 | 上海市肺科医院 | Application of biotin in preparation of medicines for treating sepsis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5315076B2 (en) * | 1973-09-27 | 1978-05-22 | ||
| JP2945680B2 (en) * | 1988-09-09 | 1999-09-06 | 旭硝子株式会社 | Peptide derivatives and their uses |
| US5087561A (en) * | 1990-06-28 | 1992-02-11 | Merck & Co., Inc. | Humoral hypercalcemic factor antagonists modified at position 13 by biotin |
| DE4310643A1 (en) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclic adhesion inhibitors |
| US5462939A (en) * | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
| DE4336758A1 (en) * | 1993-10-28 | 1995-05-04 | Merck Patent Gmbh | Linear Adhesion Inhibitors |
-
1995
- 1995-09-14 DE DE19534016A patent/DE19534016A1/en not_active Withdrawn
-
1996
- 1996-07-17 TW TW085108686A patent/TW517063B/en not_active IP Right Cessation
- 1996-08-13 HU HU9602223A patent/HUP9602223A3/en unknown
- 1996-09-09 AU AU65518/96A patent/AU719307B2/en not_active Ceased
- 1996-09-09 CZ CZ19962629A patent/CZ291506B6/en not_active IP Right Cessation
- 1996-09-10 AT AT96114454T patent/ATE215558T1/en active
- 1996-09-10 DE DE59608995T patent/DE59608995D1/en not_active Expired - Lifetime
- 1996-09-10 DK DK96114454T patent/DK0771818T3/en active
- 1996-09-10 ES ES96114454T patent/ES2174007T3/en not_active Expired - Lifetime
- 1996-09-10 SI SI9630482T patent/SI0771818T1/en unknown
- 1996-09-10 PT PT96114454T patent/PT771818E/en unknown
- 1996-09-10 EP EP96114454A patent/EP0771818B1/en not_active Expired - Lifetime
- 1996-09-10 SK SK1156-96A patent/SK283129B6/en unknown
- 1996-09-11 MX MX9604019A patent/MX9604019A/en not_active IP Right Cessation
- 1996-09-12 CN CNB961125985A patent/CN1168738C/en not_active Expired - Fee Related
- 1996-09-12 CA CA002185394A patent/CA2185394C/en not_active Expired - Fee Related
- 1996-09-12 BR BR9603741A patent/BR9603741A/en active Search and Examination
- 1996-09-13 KR KR1019960039768A patent/KR970015597A/en not_active Application Discontinuation
- 1996-09-13 NO NO19963851A patent/NO314694B1/en unknown
- 1996-09-13 ZA ZA967765A patent/ZA967765B/en unknown
- 1996-09-13 JP JP26372696A patent/JP4127325B2/en not_active Expired - Fee Related
- 1996-09-13 RU RU96118231/04A patent/RU2171807C2/en not_active IP Right Cessation
- 1996-09-13 PL PL96316069A patent/PL316069A1/en unknown
- 1996-09-13 UA UA96093556A patent/UA41981C2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0771818A3 (en) | 1997-07-02 |
| CA2185394C (en) | 2007-05-01 |
| ATE215558T1 (en) | 2002-04-15 |
| UA41981C2 (en) | 2001-10-15 |
| TW517063B (en) | 2003-01-11 |
| AU6551896A (en) | 1997-03-20 |
| HU9602223D0 (en) | 1996-10-28 |
| BR9603741A (en) | 1998-06-02 |
| NO314694B1 (en) | 2003-05-05 |
| HUP9602223A3 (en) | 1998-03-02 |
| SI0771818T1 (en) | 2002-10-31 |
| ZA967765B (en) | 1997-03-26 |
| KR970015597A (en) | 1997-04-28 |
| EP0771818B1 (en) | 2002-04-03 |
| PL316069A1 (en) | 1997-03-17 |
| DE59608995D1 (en) | 2002-05-08 |
| AU719307B2 (en) | 2000-05-04 |
| MX9604019A (en) | 1997-03-29 |
| CA2185394A1 (en) | 1997-03-15 |
| SK115696A3 (en) | 1997-05-07 |
| ES2174007T3 (en) | 2002-11-01 |
| HUP9602223A2 (en) | 1997-06-30 |
| SK283129B6 (en) | 2003-02-04 |
| CZ262996A3 (en) | 1998-02-18 |
| NO963851D0 (en) | 1996-09-13 |
| CN1153784A (en) | 1997-07-09 |
| CZ291506B6 (en) | 2003-03-12 |
| DE19534016A1 (en) | 1997-03-20 |
| EP0771818A2 (en) | 1997-05-07 |
| JP4127325B2 (en) | 2008-07-30 |
| PT771818E (en) | 2002-09-30 |
| DK0771818T3 (en) | 2002-07-29 |
| CN1168738C (en) | 2004-09-29 |
| RU2171807C2 (en) | 2001-08-10 |
| JPH09124692A (en) | 1997-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850003417A (en) | Method of producing polypeptide | |
| HUT58352A (en) | Process for producing new proteines | |
| KR940005670A (en) | Peptide | |
| IL122243A (en) | Somatostain peptides, a process for their preparation and pharmaceutical compositions comprising the same | |
| ATE386118T1 (en) | CNP GENE AND PRECURSOR PROTEIN FROM PORK | |
| DE3875538D1 (en) | AMINOLUCIFERINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE. | |
| ZA9394B (en) | A novel human kunitz-type inhibitor and variants thereof | |
| NZ333606A (en) | Isolated peptides derived from MAGE-2 | |
| KR840007569A (en) | Preparation of GRF Analog Peptides | |
| KR870007203A (en) | Methods for making peptides | |
| ES2054365T3 (en) | INHIBITION OF THE ROUTE OF THE FINAL N RULE IN LIVING CELLS. | |
| DE60144561D1 (en) | N AND / OR C TERMINAL WITH SHORT-LOADED PEPTIDE SEQUENCES MODIFIED PEPTIDES | |
| NO963851D0 (en) | biotin derivative | |
| EP0751148A3 (en) | D-amino acid substitution analogues of Magainin peptides | |
| ATE290088T1 (en) | METHOD FOR CLIVING A CHIMERIC PROTEIN USING A 'PROCESSING' ENZYME | |
| Kimura et al. | Total synthesis of human parathyroid hormone (1–84) | |
| EP0687685A4 (en) | Physiologically active peptide | |
| MX9709962A (en) | Somatostatin peptides. | |
| Zhao et al. | A novel approach for iodolabelling synthetic peptides | |
| AU2003259309A8 (en) | Peptides having affinity for a phospholipid and uses | |
| KR890002234A (en) | Peptides with vasodilation, sodium excretion and diuretic activity, preparation method thereof, preparations containing same, and use thereof | |
| KR880013972A (en) | Peptides, a Hypothalamic Growth Hormone-releasing Element (hGRF) Analog |